Federico Felizzi

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Louis Fehrenbacher, Joachim von Pawel, Keunchil Park et al. · Journal of Thoracic Oncology · 2018 · 261 citations · Full text

Medicine, Oncology, Pharmacology +12

Excitotoxicity Downregulates TrkB.FL Signaling and Upregulates the Neuroprotective Truncated TrkB Receptors in Cultured Hippocampal and Striatal Neurons

João R. Gomes, João T. Costa, Carlos V. Melo et al. · Journal of Neuroscience · 2012 · 94 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force

William V. Padula, Noémi Kreif, David J. Vanness et al. · Value in Health · 2022 · 78 citations

Social Sciences, Health Policy, Health Sciences +15

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel et al. · Clinical Lung Cancer · 2018 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mixture Cure Models in Oncology: A Tutorial and Practical Guidance

Federico Felizzi, Noman Paracha, Johannes Pöhlmann et al. · PharmacoEconomics - Open · 2021 · 43 citations · Full text

Medicine, Biostatistics, Oncology +15